Author

A. I. Doseff

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Research Focus:synaptic & neural circuits· 1

Frequent Co-Authors

A. Gilad· 1 shared B. Chen· 1 shared E. Chekalin· 1 shared K. A. Gallo· 1 shared K. Dhusia· 1 shared N. M. Desmet· 1 shared P. A. Newbury· 1 shared R. R. Neubig· 1 shared

Activity by Year

2020-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Gilad

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Bioengineering of genetically encoded gene promoter repressed by flavonoids for constructing intracellular sensor for molecular events

N. M. Desmet, K. Dhusia, W. Qi, A. I. Doseff, S. Bhattacharya, A. Gilad

The paper develops a synthetic gene promoter repressed by flavonoids to create an intracellular sensor for molecular events.

bioRxiv · Feb 17, 2021Bioengineering

Ibrutinib blocks YAP1 activation and reverses BRAFi resistance in melanoma cells

S. A. Misek, P. A. Newbury, E. Chekalin, S. Paithankar, A. I. Doseff, B. Chen, K. A. Gallo, R. R. Neubig

This study identifies ibrutinib as a drug that reverses BRAFi resistance in melanoma by inhibiting YAP1 and acting through SRC kinase off-target effects, not BTK.

bioRxiv · Mar 25, 2020Cancer Biology